LivaNova PLC (LIVN) shareholders
Close on Nov 18, 2026Market cap $5.21BP/E 27.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,922,335 | 12.70% | 13G (passive) amendment | Jun 30, 2025 |
| Primecap Management Co/Ca/ | 4,224,852 | 7.74% | 13G (passive) amendment | Dec 31, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (7.10%) | 3,897,920 | 7.10% | 13G (passive) amendment | Sep 30, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.40%), Israel A. Englander (5.40%) | 2,970,114 | 5.40% | 13G (passive) amendment | Sep 30, 2025 |
| Invesco Ltd. | 2,928,425 | 5.30% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LIVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,565,342 | 13.73% | $622.10M | +426,434 | 0.01% |
| Primecap Management Co/Ca/ | 4,168,377 | 7.57% | $342.77M | −38,675 | 0.20% |
| FMR LLC | 3,147,068 | 5.71% | $258.78M | +480,394 | 0.01% |
| Hood River Capital Management LLC | 2,565,477 | 4.66% | $210.96M | +1,928,937 | 1.53% |
| Aqr Capital Management LLC | 2,356,191 | 4.28% | $191.02M | −138,181 | 0.07% |
| Invesco Ltd. | 2,237,319 | 4.06% | $183.97M | +613,110 | 0.01% |
| Artisan Partners Limited Partnership | 2,224,763 | 4.04% | $182.94M | +101,947 | 0.29% |
| State Street Corp | 2,165,863 | 3.93% | $178.10M | +93,184 | 0.01% |
| American Century Companies Inc | 2,013,774 | 3.66% | $165.59M | +218,839 | 0.07% |
| Dimensional Fund Advisors LP | 1,845,285 | 3.35% | $151.74M | +19,037 | 0.03% |
| Geode Capital Management, LLC | 1,755,648 | 3.19% | $144.39M | +257,877 | 0.01% |
| Wellington Management Group Llp | 1,739,167 | 3.16% | $143.01M | −151,482 | 0.02% |
| Congress Asset Management Co /Ma | 1,502,244 | 2.73% | $123.53M | +227,424 | 0.76% |
| Vanguard Portfolio Management LLC | 1,414,832 | 2.57% | $116.34M | +70,543 | 0.01% |
| Greenhouse Funds LLLP | 924,128 | 1.68% | $75.99M | +155,833 | 3.88% |
| Victory Capital Management Inc | 851,820 | 1.55% | $70.05M | +18,552 | 0.04% |
| Emerald Advisers, LLC | 787,101 | 1.43% | $64.72M | +116,894 | 1.52% |
| Nuveen, LLC | 727,968 | 1.32% | $59.86M | −192,375 | 0.01% |
| Northern Trust Corp | 697,776 | 1.27% | $57.38M | +31,466 | 0.01% |
| Goldman Sachs Group Inc | 695,721 | 1.26% | $57.21M | −103,230 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 303 | 59M | 100.0% | 54 / 120 | 84 / 36 | 7M | 6M |
| Q1 2026 | 292 | 59M | 100.0% | 55 / 118 | 82 / 31 | 13M | 7M |
| Q4 2025 | 273 | 55M | 99.6% | 43 / 104 | 89 / 34 | 6M | 7M |
| Q3 2025 | 271 | 55M | 100.0% | 48 / 88 | 109 / 26 | 7M | 7M |
| Q2 2025 | 252 | 55M | 100.0% | 41 / 104 | 82 / 36 | 9M | 8M |
| Q1 2025 | 249 | 54M | 97.8% | 35 / 100 | 88 / 40 | 8M | 8M |
| Q4 2024 | 256 | 54M | 98.8% | 48 / 109 | 69 / 34 | 8M | 6M |
| Q3 2024 | 243 | 52M | 94.9% | 46 / 83 | 90 / 30 | 13M | 9M |
| Q2 2024 | 230 | 55M | 100.0% | 35 / 87 | 80 / 35 | 8M | 10M |
| Q1 2024 | 231 | 57M | 100.0% | 47 / 82 | 72 / 29 | 8M | 5M |
| Q4 2023 | 215 | 55M | 100.0% | 34 / 72 | 83 / 28 | 5M | 3M |
| Q3 2023 | 211 | 54M | 97.2% | 30 / 68 | 89 / 18 | 5M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
137 funds held LIVN in Q2 2026, 20% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LIVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Capital Opportunity Fund | 1,902,700 | 3.45% | $156.46M | 0.48% | Jun 30, 2026 |
| Invesco Small Cap Value Fund | 1,679,556 | 3.05% | $134.60M | 1.21% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 1,616,502 | 2.93% | $119.30M | 0.44% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 629,753 | 1.14% | $51.78M | 0.05% | Jun 30, 2026 |
| Vanguard Primecap Core Fund | 582,430 | 1.06% | $47.89M | 0.27% | Jun 30, 2026 |
| Oberweis Micro-Cap Fund | 447,300 | 0.81% | $36.78M | 2.28% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF | 373,124 | 0.68% | $29.90M | 0.55% | Jul 31, 2026 |
| Touchstone Strategic Trust-Touchstone Small Company Fund | 361,636 | 0.66% | $29.74M | 1.73% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 336,011 | 0.61% | $27.63M | 0.23% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 280,087 | 0.51% | $20.67M | 0.12% | May 31, 2026 |
| iShares U.S. Medical Devices ETF | 257,248 | 0.47% | $21.15M | 0.70% | Jun 30, 2026 |
| Dimensional U.S. Targeted Value ETF | 206,913 | 0.38% | $16.58M | 0.11% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 202,420 | 0.37% | $16.22M | 0.40% | Jul 31, 2026 |
| SmallCap Growth Fund I | 198,650 | 0.36% | $15.92M | 0.64% | Jul 31, 2026 |
| Dimensional U.S. Small Cap ETF | 183,472 | 0.33% | $14.70M | 0.10% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vladimir Makatsaria | Chief Executive Officer, Director | 25,326 | 0.05% | Apr 1, 2026 |
| Alex Shvartsburg | Chief Financial Officer | 42,147 | 0.08% | Nov 13, 2026 |
| Anne M. Liddy | Chief Legal Officer | – | – | Sep 16, 2026 |
| Ahmet Tezel | Chief Innovation Officer | 18,782 | 0.03% | Aug 13, 2026 |
| Stefano Folli | President, Cardiopulmonary | – | – | Aug 5, 2026 |
| Franco Poletti | President, Cardiopulmonary | 12,344 | 0.02% | Apr 1, 2026 |
| Stephanie Bolton | President, Global Epilepsy | 30,566 | 0.06% | Apr 1, 2026 |
| Natalia Kozmina | Chief Human Resources Officer | 5,015 | 0.01% | Apr 1, 2026 |
| Michael Damon Hutchinson | SVP, CLO and Company Secretary | 7,920 | 0.01% | Dec 17, 2025 |
| Francesco Bianchi | Director | 4,434 | 0.01% | Sep 14, 2026 |
| Brooke Story | Director | 7,488 | 0.01% | Sep 8, 2026 |
| Jette Nygaard-Andersen | Director | 0 | – | Jun 17, 2026 |
| Susan M. Podlogar | Director | 6,128 | 0.01% | Jun 17, 2026 |
| William A. Kozy | Director | 38,248 | 0.07% | Jun 17, 2026 |
| Peter M. Wilver | Director | 10,780 | 0.02% | Jun 17, 2026 |
| Todd C. Schermerhorn | Director | 13,105 | 0.02% | Jun 17, 2026 |
| Seng Stacy Enxing | Director | 15,793 | 0.03% | Jun 17, 2026 |
| Donald Zurbay | Director | 2,560 | 0.00% | Jun 17, 2026 |
| James Christopher Barry | Director | 8,404 | 0.02% | Jun 17, 2026 |
| Sharon O'Kane | Director | 12,910 | 0.02% | Jun 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alex Shvartsburg Chief Financial Officer | Nov 12, 2026 | Sale(10b5-1 plan) | −2,500 | $90.91 | $227.28K | 42,147 |
| Francesco Bianchi Director | Sep 10, 2026 | Sale | −3,500 | $78.01 | $273.04K | 4,434 |
| Brooke Story Director | Sep 4, 2026 | Sale | −2,300 | $81.42 | $187.27K | 7,488 |
| Francesco Bianchi Director | Aug 31, 2026 | Sale | −1,650 | $79.72 | $131.54K | 7,934 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Option exercise | +12,692 | $52.68 | $668.61K | 18,782 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Sale | −2,675 | $77.74 | $207.95K | 6,090 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Returned to company | −8,589 | $77.86 | $668.74K | 10,193 |
| Ahmet Tezel Chief Innovation Officer | Aug 11, 2026 | Tax withholding | −1,428 | $77.86 | $111.18K | 8,765 |
| William A. Kozy Director | Jun 15, 2026 | Option exercise | +5,681 | – | – | 38,248 |
| William A. Kozy Director | Jun 15, 2026 | Tax withholding | −682 | $79.70 | $54.36K | 37,566 |
| Peter M. Wilver Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 10,780 |
| Peter M. Wilver Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 10,294 |
| Todd C. Schermerhorn Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 13,105 |
| Todd C. Schermerhorn Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 12,619 |
| James Christopher Barry Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 8,404 |
| James Christopher Barry Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 7,918 |
| Francesco Bianchi Director | Jun 15, 2026 | Sale | −1,200 | $80.19 | $96.23K | 9,584 |
| Francesco Bianchi Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 11,270 |
| Francesco Bianchi Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 10,784 |
| Susan M. Podlogar Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 6,128 |
| Susan M. Podlogar Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 5,642 |
| Brooke Story Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 10,274 |
| Brooke Story Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 9,788 |
| Seng Stacy Enxing Director | Jun 15, 2026 | Option exercise | +4,042 | – | – | 15,793 |
| Seng Stacy Enxing Director | Jun 15, 2026 | Tax withholding | −486 | $79.70 | $38.73K | 15,307 |
| Ahmet Tezel Chief Innovation Officer | Jun 15, 2026 | Tax withholding | −1,032 | $79.70 | $82.25K | 6,090 |
| Ahmet Tezel Chief Innovation Officer | Jun 15, 2026 | Option exercise | +2,965 | – | – | 7,122 |
| Donald Zurbay Director | Jun 15, 2026 | Option exercise | +2,560 | – | – | 2,560 |
| Donald Zurbay Director | Jun 15, 2026 | Tax withholding | −308 | $79.70 | $24.55K | 2,252 |
| Francesco Bianchi Director | May 26, 2026 | Sale | −1,800 | $75.75 | $136.35K | 7,228 |
| Natalia Kozmina Chief Human Resources Officer | Mar 30, 2026 | Tax withholding | −1,374 | $61.27 | $84.18K | 5,015 |
| Natalia Kozmina Chief Human Resources Officer | Mar 30, 2026 | Option exercise | +6,389 | – | – | 6,389 |
| Alex Shvartsburg Chief Financial Officer | Mar 30, 2026 | Tax withholding | −12,868 | $61.27 | $788.42K | 44,647 |
| Alex Shvartsburg Chief Financial Officer | Mar 30, 2026 | Option exercise | +30,835 | – | – | 57,515 |
| Vladimir Makatsaria Chief Executive Officer, Director | Mar 30, 2026 | Option exercise | +21,042 | – | – | 25,326 |
| Vladimir Makatsaria Chief Executive Officer, Director | Mar 30, 2026 | Tax withholding | −11,159 | $61.27 | $683.71K | 14,167 |
| Franco Poletti President, Cardiopulmonary | Mar 30, 2026 | Option exercise | +3,184 | – | – | 12,125 |
| Franco Poletti President, Cardiopulmonary | Mar 30, 2026 | Tax withholding | −1,370 | $61.27 | $83.94K | 10,755 |
| Stephanie Bolton President, Global Epilepsy | Mar 30, 2026 | Option exercise | +17,815 | – | – | 30,566 |
| Stephanie Bolton President, Global Epilepsy | Mar 30, 2026 | Tax withholding | −8,377 | $61.27 | $513.26K | 22,189 |
| Ahmet Tezel Chief Innovation Officer | Mar 30, 2026 | Option exercise | +3,408 | – | – | 5,343 |
| Ahmet Tezel Chief Innovation Officer | Mar 30, 2026 | Tax withholding | −1,186 | $61.27 | $72.67K | 4,157 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Tax withholding | −1,980 | $62.26 | $123.27K | 9,010 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Tax withholding | −69 | $62.26 | $4.30K | 8,941 |
| Franco Poletti President, Cardiopulmonary | Mar 11, 2026 | Option exercise | +2,140 | $57.60 | $123.26K | 10,990 |
| Franco Poletti President, Cardiopulmonary | Dec 15, 2025 | Option exercise | +967 | – | – | 9,266 |
| Franco Poletti President, Cardiopulmonary | Dec 15, 2025 | Tax withholding | −416 | $63.06 | $26.23K | 8,850 |
| Michael Damon Hutchinson SVP, CLO and Company Secretary | Dec 15, 2025 | Option exercise | +2,254 | – | – | 7,920 |
| Michael Damon Hutchinson SVP, CLO and Company Secretary | Dec 15, 2025 | Tax withholding | −1,122 | $63.06 | $70.75K | 6,798 |
| Susan M. Podlogar Director | Dec 15, 2025 | Tax withholding | −269 | $63.06 | $16.96K | 2,086 |
| Susan M. Podlogar Director | Dec 15, 2025 | Option exercise | +2,355 | – | – | 2,355 |
| Brooke Story Director | Nov 18, 2025 | Sale | −250 | $53.94 | $13.49K | 6,232 |
| Franco Poletti President, Cardiopulmonary | Sep 15, 2025 | Option exercise | +643 | – | – | 8,576 |
| Franco Poletti President, Cardiopulmonary | Sep 15, 2025 | Tax withholding | −277 | $55.43 | $15.35K | 8,299 |
| Francesco Bianchi Director | Aug 25, 2025 | Sale | −1,500 | $56.50 | $84.75K | 9,028 |
| Peter M. Wilver Director | Jun 15, 2025 | Tax withholding | −410 | $45.76 | $18.76K | 6,738 |
| Peter M. Wilver Director | Jun 15, 2025 | Option exercise | +3,416 | – | – | 7,148 |
| Francesco Bianchi Director | Jun 15, 2025 | Option exercise | +3,416 | – | – | 10,938 |
| Francesco Bianchi Director | Jun 15, 2025 | Tax withholding | −410 | $45.76 | $18.76K | 10,528 |
| William A. Kozy Director | Jun 15, 2025 | Tax withholding | −581 | $45.76 | $26.59K | 32,567 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LivaNova's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,066 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Francesco Bianchi Officer | Sep 10, 2026 | 3,500 | $273.03K | Sep 10, 2026 | Vesting of restricted stock unit award |
| Brooke Story Officer | Sep 4, 2026 | 2,300 | $187.27K | Sep 4, 2026 | Vesting of restricted stock unit award |
| Franco Poletti Officer | Sep 2, 2026 | 10,755 | $882.89K | Sep 2, 2026 | Vesting of restricted stock unit awards |
| Francesco Bianchi Officer | Aug 31, 2026 | 1,650 | $131.54K | Aug 31, 2026 | Vesting of restricted stock unit award |
| Ahmet Tezel Officer | Aug 11, 2026 | 2,675 | $209.94K | Aug 11, 2026 | Exercise of employee stock appreciation rights |
| Francesco Bianchi Officer | Jun 15, 2026 | 1,200 | $96.23K | Jun 15, 2026 | Vesting of restricted stock unit award |
| Francesco Bianchi Officer | May 26, 2026 | 1,800 | $136.35K | May 26, 2026 | Vesting of restricted stock unit award |
| Brooke Story Director | Nov 18, 2025 | 250 | $13.49K | Nov 18, 2025 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Aug 25, 2025 | 1,500 | $84.75K | Aug 25, 2025 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Dec 11, 2024 | 1,250 | $63.74K | Dec 11, 2024 | Vesting of restricted stock unit award |
| Trui Hebbelinck Officer | Dec 10, 2024 | 6,000 | $301.62K | Dec 10, 2024 | Vesting of restricted stock unit award |
| Francesco Bianchi Director | Sep 11, 2024 | 1,500 | $69.87K | Sep 11, 2024 | Vesting of restricted stock unit award |
| Daniel Jeffrey Moore Director | Jun 3, 2024 | 56,623 | $3.40M | Jun 3, 2024 | Exercise of employee stock options |
| McDonald Damien Officer | Jun 23, 2023 | 20,000 | $990.00K | Jun 23, 2023 | Vesting of restricted stock unit award |
| McDonald Damien Officer | Jun 20, 2023 | 8,847 | $452.32K | Jun 20, 2023 | Exercise of employee stock appreciation rights |
See a number that looks wrong?